0 0 0 0 0 0 0.00196555521694468 -0.000291850282417617
Sign Up Today X
Thanks for submitting the form.
Stockreport

Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
TURKU, FI / ACCESS Newswire / December 22, 2025 / Faron Pharmaceuticals Ltd. (AIM:ARN, First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, today announces the finalization of agreements to initiate the BLAZE trial, a new investigator-initiated trial (IIT) in the UK. The trial is conducted via a strategic collaboration with The Institute of Cancer Research, London (ICR), operating in partnership with The Royal Marsden NHS Foundation Trust. This collaboration leverages the world-class expertise of these globally recognized leaders in cancer research, innovation, and treatment. The Phase I/II BLAZE trial will investigate Faron's lead asset, bexmarilimab , in combination with the anti-PD-1 checkpoint inhibitor, zimberelimab provided by Gilead Sciences, for patients with metastatic non-small cell lung cancer (NSCLC) and melanoma who have developed resistance to prior anti-PD-1-based immunotherapy and progressed within three months of the last anti-PD-1 t [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
TURKU, FI / ACCESS Newswire / December 22, 2025 / Faron Pharmaceuticals Ltd. (AIM:ARN, First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, today announces the finalization of agreements to initiate the BLAZE trial, a new investigator-initiated trial (IIT) in the UK. The trial is conducted via a strategic collaboration with The Institute of Cancer Research, London (ICR), operating in partnership with The Royal Marsden NHS Foundation Trust. This collaboration leverages the world-class expertise of these globally recognized leaders in cancer research, innovation, and treatment. The Phase I/II BLAZE trial will investigate Faron's lead asset, bexmarilimab , in combination with the anti-PD-1 checkpoint inhibitor, zimberelimab provided by Gilead Sciences, for patients with metastatic non-small cell lung cancer (NSCLC) and melanoma who have developed resistance to prior anti-PD-1-based immunotherapy and progressed within three months of the last anti-PD-1 t [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS